As a fifth consecutive year winner, Clinipace Worldwide has been added to the Inc. 5000 Honor Roll, which recognizes five-time overall honorees and is bestowed to few other companies in the nation. The company generated a three-year growth rate of 372% and added 420 jobs from 2011 to 2013.
As a global full-service digital CRO, Clinipace Worldwide has pioneered an innovative service model to transform drug and medical device development that serves the unique needs of emerging, venture-backed and mid-tier life sciences firms.
“We’re honored to be included in the Inc. 5000 Honor Roll as a fifth consecutive year winner, which is not often achieved,” said Jeff Williams, CEO, Clinipace Worldwide. “This accomplishment would not be possible without the dedication and expertise of our employees. We look forward to growing our global capacity, and delivering the most innovative research services and technology to support the most forward-thinking clients within our industry.”
This year’s winners will be honored at the 33rd Annual Inc. 500|5000 Conference and Awards Ceremony October 15-17 at the JW Marriott Desert Ridge Resort & Spa in Phoenix, Arizona.
About Inc. 500|5000 List
The Inc. 500|5000 is a list of the fastest-growing private companies in the nation. Started in 1982, this prestigious list of the nation’s most successful private companies has become the hallmark of entrepreneurial success. The Inc. 5000 Conference & Awards Ceremony is an annual event that celebrates their remarkable achievements. The event also offers informative workshops, celebrated keynote speakers, and evening functions. For more information on Inc. and the Inc. 5000 Conference, visit http://www.inc.com/.
About Clinipace Worldwide
As a global full-service digital contract research organization (dCRO), we have pioneered an innovative technology-amplified CRO service model to serve the unique needs of venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device firms. Powered by TEMPO™, our proprietary eClinical platform, our team of experts brings extensive therapeutic knowledge and insight into assisting life science firms in developing and executing regulatory strategies, clinical development, and post-approval research to ensure a successful drug and medical device development program. We have managed over 1,800 global clinical research, strategic product development, regulatory, and GxP/CMC/QA projects in therapeutic areas such as cardiovascular & metabolic diseases, central nervous system, dermatology, gastroenterology, immunology, infectious diseases, nephrology, oncology, respiratory, rheumatology, and vaccines (and other cell and tissue based therapies). Clinipace Worldwide has its global headquarters in Research Triangle Park, NC with additional domestic operations in Irvine, CA, Overland Park, KS, and Boulder, CO; European operations in Zurich, Switzerland, Munich, Germany, and London, United Kingdom; Asian operations in Taipei, Taiwan, China offices in Beijing, Shanghai, Guangzhou, Seoul, South Korea, Hong Kong, Hanoi, Vietnam, Singapore, Kuala Lumpur, Malaysia; South American operations based in Sao Paulo, Brazil, Buenos Aires, Argentina, and Lima, Peru; Middle Eastern operations in Tel-Aviv, Israel and Indian operations in Trivandrum and New Delhi, India. For more information, visit our website at www.clinipace.com.